Generic placeholder image

Current Pharmaceutical Design

Editor-in-Chief

ISSN (Print): 1381-6128
ISSN (Online): 1873-4286

Review Article

Antiplatelet and Anticoagulation Therapy in Structural Heart Disease Interventions Beyond TAVI

Author(s): Manolis Vavuranakis*, Konstantinos Dean Boudoulas, Ourania Katsarou, Dimitrios A. Vrachatis, Konstantinos I. Kalogeras, Theodore G. Papaioannou, Gerasimos Siasos, Evangelos Oikonomou, George Lazaros, Michael-Andreas Vavuranakis, Spyridon Deftereos and Dimitrios Tousoulis

Volume 23 , Issue 9 , 2017

Page: [1328 - 1333] Pages: 6

DOI: 10.2174/1381612822666161221143416

Price: $65

Abstract

Transcatheter interventions for structural heart disease represent an emerging field in interventional cardiology. Undoubtedly, there is an absolute necessity for antiplatelet and/or anticoagulation treatment prior, during and post such interventions. However, currently administered regimens are mainly based in expert consensus recommendations. In the present review we aim to summarize data regarding anti platelet and/or anticoagulation treatment in the following transcatheter structural heart interventions: left atrial appendage closure, atrial septal defect closure, patent foramen oval closure, paravalvular leak closure.

Keywords: ASD, LAA, PFO, transcatheter, warfarin, coumadin, antiplatelet, NOAC.


Rights & Permissions Print Export Cite as
© 2022 Bentham Science Publishers | Privacy Policy